Chairman of the Board
Mr. Swirsky currently serves as President and Chief Financial Officer of Rexahn Pharmaceuticals, Inc., a publicly-traded clinical-stage oncology company. Prior to joining Rexahn, Mr. Swirsky served as President and Chief Executive Officer, and a Director of GenVec, Inc.; a position he held from 2013 through the sale of the company in June 2017. From 2006 through 2014, he served as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of GenVec. Prior to joining GenVec in September 2006, Mr. Swirsky worked at Stifel Nicolaus where he served as a Managing Director and the head of Life Sciences Investment Banking. Previously, Mr. Swirsky held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason. His experience also includes positions in public accounting and consulting. Mr. Swirsky currently serves as Chairman of the Board of Fibrocell Science, Inc. and a member of the Board of Directors of Pernix Therapeutics Holdings, Inc. He received his undergraduate degree in Business Administration from Boston University and his Master of Business Administration from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a Certified Public Accountant and a CFA® charter holder.